
|Articles|August 31, 2012
Trastuzumab Link to Heart Failure Seen
Advertisement
Treatment with trastuzumab (Herceptin) boosts risk of heart failure or cardiomyopathy in breast cancer survivors, an observational study affirmed.
Women who received trastuzumab alone were 4.12 times more likely (95% CI 2.30 to 7.42) to go into heart failure after accounting for other factors, Erin Aiello Bowles, MPH, of the Group Health Research Institute in Seattle, and colleagues found.
Read the full story:
Source: MedPage Today
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Single-Dose Oral Antibiotic Zoliflodacin Treats Drug-Resistant Gonorrhea
2
FDA Approves Inebilizumab for Generalized Myasthenia Gravis
3
Evaluation of Albumin Platelet Product for Fibrosis Detection in MASLD
4
Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD
5












































